68ga−psma−hbed−cc
Small moleculeexperimentalImaging agent
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 22, 2017 (NCT03327675)
Timeline
Indications
Studied for
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 68-gallium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04402151 | Phase 2 | Jun 30, 2020 | Cornell University, National Cancer Institute (NCI) |
| NCT03545165 | Phase 1/Phase 2 (Phase 2) | Apr 18, 2018 | Cornell University |
| NCT03439033 | Phase 2 | Apr 3, 2018 | Cornell University |
| NCT03327675 | N/A | Sep 22, 2017 | Katholieke Universiteit Leuven |
| NCT04452136 | N/A | — | OHSU Knight Cancer Institute, Oregon Health and Science University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cornell University | Academic/Hospital | 3 | 3 | 1 | 2018 |
| Katholieke Universiteit Leuven | Academic/Hospital | 1 | 1 | 1 | 2017 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2020 |
| OHSU Knight Cancer Institute | Academic/Hospital | 1 | 0 | 1 | — |
| Oregon Health and Science University | Academic/Hospital | 1 | 1 | 1 | — |
5 organizations
Page 1 / 1